Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)

被引：69
|
作者：
Xin, Xin [1 ]
Chen, Cheng [1 ]
Hu, Yi-Yang [1 ,2 ,3 ]
Feng, Qin [1 ,2 ,3 ]
机构：
[1] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Liver Dis, Shanghai 201203, Peoples R China
[2] Shanghai Key Lab Tradit Chinese Clin Med, Shanghai 201203, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Key Lab Liver & Kidney Dis, Minist Educ, Shanghai 201203, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2019年 / 117卷
基金：
中国国家自然科学基金;
关键词：
Genistein; Soy; Nonalcoholic steatohepatitis (NASH); Non-alcoholic fatty liver disease (NAFLD); Review; CARDIOVASCULAR RISK-FACTORS; KINASE INHIBITOR GENISTEIN; GENE-EXPRESSION PROFILES; ACTIVATED PROTEIN-KINASE; POSTMENOPAUSAL WOMEN; LIPID-METABOLISM; HEPATOCELLULAR-CARCINOMA; PHYTOESTROGEN GENISTEIN; DIETARY PHYTOESTROGENS; HEPATIC STEATOSIS;
D O I：
10.1016/j.biopha.2019.109047
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
NAFLD is a vital health problem worldwide; however, no effective treatment is currently available for NAFLD. Intensive studies have indicated the efficacy of genistein (GE), a bioactive isoflavone extracted from soy, in treating NAFLD. In addition to its oestrogen-like effects, GE is known to have multiple molecular effects, for instance, lipid and glucose metabolism-promoting effects and activities against lipid peroxidation, inflammation, fibrosis, and NAFLD-related tumours. Here, this review summarizes the potential role of GE in the treatment and prevention of NAFLD and some of the currently known targets and signalling pathways of GE in NAFLD.
引用
收藏
页数：11
相关论文
共 50 条
  • [1] Nonalcoholic Fatty Liver disease (NAFLD)
    Zeuzem, S.
    Trautwein, C.
    GASTROENTEROLOGE, 2020, 15 (02): : 77 - 77
  • [2] Pathogenesis of nonalcoholic fatty liver disease (NAFLD)
    Farrell, Geoffrey C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A30 - A30
  • [3] Nonalcoholic fatty liver disease (NAFLD) in children
    Sathya, P
    Martin, S
    Alvarez, F
    CURRENT OPINION IN PEDIATRICS, 2002, 14 (05) : 593 - 600
  • [4] Die nichtalkoholische Fettlebererkrankung (NAFLD)Nonalcoholic fatty liver disease (NAFLD)
    S. Zeuzem
    C. Trautwein
    Der Gastroenterologe, 2020, 15 (2): : 77 - 77
  • [5] Noninvasive Diagnostics in Nonalcoholic Fatty Liver Disease (NAFLD)
    Stauber R.
    Journal für Gastroenterologische und Hepatologische Erkrankungen, 2019, 17 (3) : 75 - 81
  • [6] An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
    Lomonaco, Romina
    Chen, Janet
    Cusi, Kenneth
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2011, 2 (05) : 211 - 225
  • [7] Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD)
    Itoh, Hiroaki
    Kanayama, Naohiro
    DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE (DOHAD): FROM BIOLOGICAL BASIS TO CLINICAL SIGNIFICANCE, 2018, 1012 : 29 - 39
  • [8] Vitamin E and nonalcoholic fatty liver disease (NAFLD)
    Thakur, Varsha
    Ulatowski, Lynn
    Parker, Robert
    Zhang, Renliang
    Liu, Xiuli
    Manor, Danny
    FASEB JOURNAL, 2013, 27
  • [9] Nutritional Management of Nonalcoholic fatty liver disease (NAFLD)
    Boudaoud, Amel Ait
    Rives-Lange, Claire
    Perregaux, Jean Francois
    Radu, Alina
    Messager-Josipowicz, Diane
    Barsamian, Charles
    Carette, Claire
    Czernichow, Sebastien
    PRESSE MEDICALE, 2019, 48 (12): : 1496 - 1501
  • [10] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
12345